ibritumomab tiuxetan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
chelating agents 4984 206181-63-7

Description:

MoleculeDescription

Synonyms:

  • ibritumomab tiuxetan (90Y)
  • ibritumomab tiuxetan
  • zevalin
  • IDEC-Y2B8
90Y-labeled anti-CD20 monoclonal antibody for radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
  • Molecular weight: 660.50
  • Formula: C23H32N5O10SY
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 16, 2004 EMA
Feb. 19, 2002 FDA SPECTRUM PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 84.46 35.49 46 1035 126535 46558446
Bone marrow failure 84.39 35.49 30 1051 29639 46655342
Progressive multifocal leukoencephalopathy 75.89 35.49 22 1059 11324 46673657
Stem cell transplant 67.83 35.49 14 1067 1752 46683229
Myelodysplastic syndrome 64.73 35.49 21 1060 15690 46669291
Neutropenia 41.97 35.49 31 1050 143173 46541808
Enterococcal infection 39.90 35.49 12 1069 6975 46678006
Pancytopenia 38.20 35.49 24 1057 85034 46599947

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myelodysplastic syndrome 91.18 34.28 34 1384 18744 29932316
Venoocclusive liver disease 51.32 34.28 17 1401 6596 29944464
Acute myeloid leukaemia 44.09 34.28 20 1398 17986 29933074
Bone marrow failure 42.79 34.28 23 1395 29762 29921298
Stem cell transplant 40.75 34.28 11 1407 2120 29948940
Thrombocytopenia 39.65 34.28 40 1378 137004 29814056
Meningitis tuberculous 37.66 34.28 8 1410 557 29950503
White blood cell count decreased 36.91 34.28 31 1387 83916 29867144
Platelet count decreased 34.42 34.28 33 1385 106096 29844964
Neutropenia 34.40 34.28 36 1382 128504 29822556

Pharmacologic Action:

SourceCodeDescription
ATC V10XX02 VARIOUS
THERAPEUTIC RADIOPHARMACEUTICALS
OTHER THERAPEUTIC RADIOPHARMACEUTICALS
Various therapeutic radiopharmaceuticals
FDA MoA N0000000205 Radiopharmaceutical Activity
FDA MoA N0000175078 CD20-directed Antibody Interactions
FDA EPC N0000175658 CD20-directed Radiotherapeutic Antibody

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Follicular non-Hodgkin's lymphoma indication 308121000

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
B-lymphocyte antigen CD20 Surface antigen ANTIBODY BINDING Kd 7.85 DRUG LABEL DRUG LABEL

External reference:

IDSource
D04489 KEGG_DRUG
4021301 VUID
N0000148737 NUI
4021301 VANDF
C0877880 UMLSCUI
CHEMBL1201606 ChEMBL_ID
CHEMBL2108667 ChEMBL_ID
DB00078 DRUGBANK_ID
C422802 MESH_SUPPLEMENTAL_RECORD_UI
6777 IUPHAR_LIGAND_ID
7873 INN_ID
4Q52C550XK UNII
262323 RXNORM
17128 MMSL
d04845 MMSL
009576 NDDF
385546007 SNOMEDCT_US
385548008 SNOMEDCT_US

Pharmaceutical products:

None